Zhengping Wang

机构：Revolution Medicines (United States) · ORCID：0000-0001-5928-3816

发表论文 246 篇 · 总被引 3842 次 · h-index 33

代表论文

• Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers (2025 · Journal of Medicinal Chemistry · 被引 89)
• Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers (2025 · Journal of Medicinal Chemistry · 被引 48)
• Multimodal GPT model for assisting thyroid nodule diagnosis and management (2025 · npj Digital Medicine · 被引 46)
• A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors (2025 · Science · 被引 41)
• DHA and EPA alleviate depressive-like behaviors in chronic sleep-deprived mice: Involvement of iron metabolism, oligodendrocyte-lipids peroxidation and the LCN2-NLRP3 signaling axis (2024 · Free Radical Biology and Medicine · 被引 18)
• Utilizing multiclassifier radiomics analysis of ultrasound to predict high axillary lymph node tumour burden in node-positive breast cancer patients: a multicentre study (2024 · Annals of Medicine · 被引 16)